retatrutide type 2 diabetes phase 2 results 2024 Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide: A Promising Breakthrough for

It cooks in under five minutes

In the long term, the benefits of treating obesity and preventing other diseases should outweigh the costs of treating diseases resulting from obesity

Companies like Eli Lilly and Novo Nordisk are leading the development of oral alternatives designed to match the efficacy of injectables while improving convenience and adherence

The efficacy difference is substantial

Retatrutide's Half-Life Is Approximately 6 Days In the Phase 1b multiple-ascending-dose trial, the pharmacokinetics of LY3437943 were dose proportional and its half-life was approximately 6 days (Urva et al., Lancet, 2022)